The Royal Society of Chemistry has announced that its near 180-year old archive of research insights has been made available for Text and Data Mining projects, but why is this important? Richard Kidd, Head of Chemistry Data at the Royal Society of Chemistry, explores the significance

The most advanced of the experimental coronavirus vaccines are providing glimmers of hope for advancing the battle against COVID-19, having reported late-stage data with higher than expected levels of protection.

Six medicines have taken a leap towards approval having won the backing of the European Medicines Agency's human medicines committee (CHMP).

The National Institute for Health Research (NIHR) has launched five national patient recruitment centres (NPRCs) in a move designed to accelerate the delivery of late-stage clinical research within the NHS.

A new, pooled analysis of data from Novo Nordisk’s Phase III trials SUSTAIN 6 and PIONEER 6 shows that semaglutide may help patients with type 2 diabetes live longer without a cardiovascular event. PharmaTimes talks to lead study investigator Dr Jan Westerink about the importance of these findings

Digital has been waiting for pharma to join the party for a very long time. In the last few years, however, our industry has finally hit the digital dance floor, inviting the production line of constantly evolving technology to help extend, transform and save lives. Since March, digital has also entered all our consciousness in a truly existential way – a way none of us could have predicted. Indeed, if there was anyone left in our industry that hadn’t realised the digital age was upon us, please be assured, they do now.

At the beginning of January this year, there was a brief news report about a virus in Wuhan that appeared to be quite virulent. That seems so long ago, yet the year has flown. Hopefully, before we know it, we will be reflecting on what we all did during lockdown and looking ahead to the challenges of 2021.

At the start of this year, the NHS was working on the next stage of its Long Term Plan and defining how key aspects, such as integrated systems and moving more care out of hospitals, would work in practice.

One of the things I will remember most vividly about this year is the glimpse it has given me of what it means to be separated from those we care about.

M&A volumes more than doubled between 2005 and 2019. By comparison, 2020 has been a slow year, with a marked decline in deal activity and a sharp drop in overall deal value.